APOE and Cognitive impairment: DMHCA represents an LXR partialagonist that despite inducing the expression of ApoE (mainly responsibleof Aβ drainage from the brain) shows nil activity invivo because of low solubility/inability to cross the BBB.Our DMHCA polymer therapeutic approach of intranasally administereddendritic micelles at very early stages of the pathology effectivelyprevents cognitive deficits assessed by the NOR test and reduces Aβdeposition without undesirable side effects, leaving the plasma levelsof cholesterol and triglycerides unaffected.